A larger cross-sectional analysis of 1328 men with prostate cancer by Giri and colleagues [210] found 15.6% carriers of germline mutations; 10.9% patients carried a mutation in DNA repair genes (BRCA2 > CHEK2 > ATM > BRCA1), increasing the risk of more advanced tumors (Gleason score ≥ 8). This evidence concerns the gene BRCA2 and Familial prostate cancer.